Form 8-K - Current report:
SEC Accession No. 0001193125-25-002189
Filing Date
2025-01-06
Accepted
2025-01-06 16:35:52
Documents
13
Period of Report
2025-01-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d912671d8k.htm   iXBRL 8-K 24306
  Complete submission text file 0001193125-25-002189.txt   146156

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kura-20250101.xsd EX-101.SCH 2865
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20250101_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20250101_pre.xml EX-101.PRE 11271
15 EXTRACTED XBRL INSTANCE DOCUMENT d912671d8k_htm.xml XML 3639
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 25511710
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)